EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER

被引：0
|
作者：
Lu, Z. [1 ]
Li, H. [2 ]
Wada, R. [2 ]
Li, L. [1 ]
Kamiyama, E. [1 ]
Vaddady, P. [1 ]
Abutarif, M. [1 ]
Garimella, T. [1 ]
Khatri, A. [1 ]
机构：
[1] Quantitat Clin Pharmacol, Daiichi Sankyo, Tokyo, Japan
[2] QuanTx Consulting, The Woodlands, TX USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-117
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [2] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [3] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [4] T-DXd: New Standard for HER2-Low Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (08) : 1828 - 1828
  • [5] Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd)
    Lapen, Kaitlyn
    Dee, Edward Christopher Christopher
    Thom, Bridgette
    Aviki, Emeline Mariam
    Chino, Fumiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
    Hsieh, Y. Pei
    ANNALS OF ONCOLOGY, 2024, 35 : S1394 - S1394
  • [7] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Carroll, Hailey K.
    Higgins, Michaela J.
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1144 - 1144
  • [8] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [9] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [10] T-DXd for HER2-low expressing cases breast cancer at our hospital
    Noguchi, E.
    Shimizu, Y.
    Nogami, M.
    Tsukada, H.
    Natori, K.
    Aoyama, K.
    Akashi-Tanaka, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1395 - S1395
12345